Objective-Surgical hindlimb ischemia (HLI) in mice has become a valuable preclinical model to study peripheral arterial disease. We previously identified that the different phenotypic outcomes after HLI across inbred mouse strains is related to a region on the short arm of mouse chromosome 7. The gene coding the interleukin-21 receptor (IL-21R) lies at the peak of association in this region. Approach and Results-With quantitative real-time polymerase chain reaction, we found that a mouse strain with a greater ability to upregulate IL-21R after HLI had better perfusion recovery than a strain with no upregulation after HLI. Immunofluorescent staining of ischemic hindlimb tissue showed IL-21R expression on endothelial cells (ECs) from C57BL/6 mice. An EC-enriched fraction isolated from ischemic hindlimb muscle showed higher Il-21R levels than an EC-enriched fraction from nonischemic limbs. In vitro, human umbilical vein ECs showed elevated IL-21R expression after hypoxia and serum starvation. Under these conditions, IL-21 treatment increased cell viability, decreased cell apoptosis, and augmented tube formation. In vivo, either knockout Il21r or blocking IL-21 signaling by treating with IL-21R-Fc (fusion protein that blocks IL-21 binding to its receptor) in C57BL/6 mice resulted in less perfusion recovery after HLI. Both in vitro and in vivo modulation of the IL-21/IL-21R axis under hypoxic conditions resulted in increased signal transducer and activator of transcription 3 phosphorylation and a subsequent increase in the B-cell lymphoma leukemia-2/ BCL-2-associated X protein ratio.
A lthough rates of death from ischemic heart disease in the United States have fallen over the past decades, the prevalence of peripheral arterial disease (PAD) has actually increased and PAD will become an even greater healthcare problem in the years ahead as the major drivers for PAD are advancing age, smoking, and diabetes mellitus. [1] [2] [3] [4] [5] The primary problem in PAD is reduced blood flow to the leg, and because total occlusions in ≥1 more of the major inflow arteries to the leg(s) are common in patients with PAD, the magnitude of distal blood flow becomes dependent on the number and extent of collateral blood vessels that connect to the distal microvasculature. 6, 7 Current medical therapies used to treat PAD include antiplatelet agents, statins to lower cholesterol, antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin 2 receptor blocker or β-blockers, blood glucose control, and smoking cessation. 8, 9 However, there are no agents that have shown the ability to improve leg blood flow in patients with PAD and thus no medical therapies are available to directly treat the primary problem of reduced blood flow. New treatment paradigms are needed for PAD. 6 The response that follows surgically induced hindlimb ischemia (HLI) in mice has been widely used to test agents to treat PAD. 10, 11 Genetic factors modify the clinical outcomes when PAD is present. 12, 13 Our laboratory and others have shown that C57BL/6 mice recover from HLI much better than BALB/c mice. 11, 14 We previously showed that a quantitative trait locus that spans a 31 million base pair region on the short arm of mouse chromosome 7 (termed LSq-1) was sufficient to determine the extent of perfusion recovery and tissue loss after HLI, and using the outcome additional inbred mouse strains, gene blocks within this region were identified. 11 The interleukin-21 receptor (IL-21R), whose modulation is being clinically studied in a variety of disease, [15] [16] [17] lies at or near the peak of the strength of association across this region based on locations and on the NCBI37/mm10 genome ( Figure I in the online-only Data Supplement).
IL-21 is a type I cytokine whose receptor is 1 of 6 receptors that forms a heterodimeric receptor complex with the common γ chain (γ c ). 15, 18 IL-21 has pleiotropic actions and regulates the differentiation and function of lymphoid and myeloid cells. 19, 20 Because of its ability to regulate immune responses, enhancing or inhibiting the action of IL-21 or IL-21R has been demonstrated to have therapeutic effects on a wide range of diseases. 21 To the best of our knowledge, there is no information for a role of IL-21R in PAD, but phase I and II clinical trials investigating the effects of administering IL-21 as an anticancer agent or blocking IL-21R in autoimmune disease are underway. 16, 17 Here, we present data suggesting that IL-21R upregulation and activation induce a protective effect in hypoxic endothelium, and modulation of IL-21R needs to be studied in PAD.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

IL-21 Receptor mRNA Level Varies Greatly Between C57BL/6 and BALB/c in Ischemic Muscle Tissue
Although C57BL/6 and BALB/c mice have different outcomes after HLI, 11, 22 the degree of perfusion recovery was comparable at an early (day 3) time point after HLI. 11 We first studied 5 mice from each strain at day 3 post HLI by quantitative real-time polymerase chain reaction, Il21r mRNA level was much more highly upregulated in ischemic hindlimb muscles from C57BL/6 mice (≈39-fold) than from BALB/c (≈1.7-fold) mice ( Figure 1A ). Furthermore, the Il21r upregulation after ischemia in C57BL/6 mice was also found in earlier (day 1 post-HLI) and later (days 7 and 21, post-HLI) time points ( Figure II in the online-only Data Supplement).
We sought to determine whether endothelial cells (ECs) contribute to the IL21R elevation after HLI, CD31 + cells Interleukin-21 receptor (IL-21R) levels vary greatly between C57BL/6 and BALB/c mice after hindlimb ischemia (HLI). A, Three days after HLI, ischemic gastrocnemius muscle (IGA) from C57BL/6 mice showed upregulation (≈39-fold) of Il21r mRNA level compared with nonischemic gastrocnemius muscle (NIGA). BALB/c mice also showed Il21r mRNA level upregulation (≈1.7-fold) after HLI. However, the fold changes in BALB/c mice were significantly smaller than in C57BL/6 mice (P<0.001; n=5 per group). B, Il21r mRNA level of CD31 + (CD31 is an endothelial cell marker) cell isolated from C57BL/6 mouse hindlimb muscle tissue is significantly upregulated (≈160-fold) 3 days after HLI when compared with endothelial cells from nonischemic hindlimb (P<0.001, n=4-5 per group). C, Immunofluorescence of IGA and NIGA IL-21R (red), CD31 (green), and merged from wild-type (WT) or Il21r −/− C57BL/6 mice; costaining of CD31 and IL21R can be visualized in the ischemic muscle from the WT mice. IL-21R was not detected either in muscle tissue from nonischemic limb or in the ischemic muscle tissue from Il21r −/− mice. D, Fluorescence-activated cell sorter analysis in CD31 + cell fraction isolated from IGA and NIGA, IL-21R level in CD31 cells showed a significant increase in IGA compared with NIGA from C57BL/6 mouse, but did not show statistical difference from BALB/c mouse. KO indicates Il21r knockout; and NS, no statistical significance.
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were isolated from C57BL/6 hindlimb, 23 and showed a higher IL-21R mRNA expression (≈159-fold, Figure 1B ) in CD31 + cells from the ischemic side. Immunofluorescence of the ischemic muscle from C57BL/6 mice at day 3 post HLI showed numerous examples of costaining of IL-21R with CD31 ( Figure 1C ). Moreover, flow cytometry showed that CD31 + fraction from ischemic hindlimb muscle had higher IL-21R protein level than the CD31 + fraction from nonischemic hindlimb muscle in C57BL/6 mice, but CD31 + fraction from BALB/c mice did not show a difference of IL-21R between ischemic and nonischemic muscle ( Figure 1D ). We also examined the levels of IL-21 protein by Western blotting using lysates from ischemic muscle from BALB/c and C57BL/6 mice, but did not find any difference ( Figure III in the online-only Data Supplement). Thus, differences between C57BL/6 and BALB/c were at the level of the IL-21 receptor, not its ligand.
IL-21R Activation Has Prosurvival Effects in ECs Under Hypoxia Serum Starvation Conditions
The association of better outcomes after HLI in C57BL/6 mice compared with BALB/c mice and greater IL-21R expression in EC isolated from C57BL/6 ischemic muscle led us to look for an in vitro correlate. Using methods similar to those previously described, 10 in vitro ECs (human umbilical vein endothelial cells [HUVECs]) showed ≈10 fold IL-21R expression (P<0.05) when exposed to hypoxia serum starvation (HSS; Figure 2A ). Under HSS conditions that induced IL-21 receptor upregulation, treatment of HUVEC with IL-21 (50 ng/mL) increased cell viability ( Figure 2B ), reduced cell A, After 24 hours of hypoxia and serum starvation (HSS), quantitative real-time polymerase chain reaction showed ≈10-fold increase in IL21R mRNA expression when compared with HUVECs cultured under normoxia (normoxia indicates cells cultured under normal condition). B, More viable cells were detected after IL-21 (50 ng/mL) treatment for 24 hours in HSS conditions. Cell viability assay is based on the cleavage of the tetrazolium salt to formazan by cellular mitochondrial dehydrogenase. C, In situ terminal dUTP nick end-labeling (TUNEL) showed that IL-21 (50 ng/mL) treatment for 24 hours decreases HUVEC cell apoptosis in HSS conditions. D, HUVECs were plated on matrigel with reduced growth factor and incubated for 10 hours in HSS conditions with basal or treatment medium, IL-21-treated HUVECs showed enhanced tube formation, which was quantified as total length of the cords per visual filed, and total loops per visual field as represented by the bar graph. The IL-21 effects on HUVECs viability, apoptosis, and tube formation (B-D) were inhibited when IL-21R expression was knocked down using small hairpin RNA. All the above data are representative of 2 to 3 separate batches of HUVECs, n=8 to 12 samples per group. EV indicates empty vector; NS, no statistical significance; and Sh-IL21R, IL-21R knockdown using small hairpin RNA.
apoptosis ( Figure 2C ), and enhanced endothelial tube formation in Matrigel models ( Figure 2D ). The specificity of these effects induced by IL-21 was demonstrated by the inhibition of survival benefit when using human IL21R small hairpin RNA ( 
IL-21 Treatment Regulates the Signal Transducer and Activator of Transcription 3 Pathway in ECs Under HSS
Signal transducer and activator of transcription (STAT) 1, STAT3, protein kinase B (AKT), and extracellular A, After cultured under HSS conditions for 24 hours, HUVECs were treated with 50 ng/mL IL-21 or saline (control) for 15 minutes and then harvested for Western blotting. IL-21 treatment induced higher STAT3 phosphorylation, but did not significantly change STAT1, protein kinase B (AKT), or extracellular signal-regulated kinases1/2 (ERK1/2) phosphorylation. The IL-21 effects on STAT3 phosphorylation were inhibited when IL-21R expression was knocked down using small hairpin RNA (shRNA). B, Phosphorylation of STAT3 is not changed with IL-21 treatment when Janus kinase 3 was inhibited by tofacitinib. C, Western blotting of HUVEC 24 hours after IL-21 treatment under HSS conditions showed higher BCL-2/BAX ratio compared with saline treated. The IL-21 effects on BCL-2/BAX increase were blunted when IL-21R were knocked down by shRNA. D, BCL-2/BAX ratio is not changed with IL-21 treatment when STAT3 was inhibited by S3I-201. The above data are representative of 2 separate batches of HUVECs, n=4 per group. DMSO indicates dimethyl sulfoxide; P-ERK1/2, phospho-ERK1/2; and p-STAT, phospho-STAT. EV indicates empty vector; NS, no statistical significance; and Sh-IL21R, IL-21R knockdown using small hairpin RNA. signal-regulated kinases1/2 (ERK1/2) pathways are activated by IL-21 in various cell types under different conditions. 19, 25 To test whether these signaling pathways were activated by IL-21 treatment under HSS conditions, we performed Western blot analysis on protein lysates from HUVECs. After 24-hour exposure to HSS conditions, which induces IL-21R expression, HUVECs were treated with 50 ng/mL IL-21 for a series of time points. IL-21 induced peak increase of STAT3 phosphorylation 15 minutes after treatment, but did not show significant changes in STAT1, AKT1, or ERK1/2 phosphorylation at any time point ( Figure VIII in the online-only Data Supplement). The IL-21-induced STAT3 phosphorylation was abolished by either IL-21R small hairpin RNA or Janus kinase 3 inhibitor (tofacitinib, 5 μmol/L; Figure 3A and 3B), which indicated that IL-21 activates STAT3 pathways via IL-21R and Janus kinase 3 in hypoxic ECs.
The ratio of B-cell lymphoma leukemia-2 (BCL-2)/BCL-2-associated X protein (BAX) expression has been reported to be regulated by STAT3 phosphorylation. 26 To investigate whether BCL-2 or BAX expression was modulated in our experiment, HUVECs were treated with IL-21 under HSS conditions, which showed increased ratio of BCL-2/BAX 24 hour after treatment compared with vehicle treatment by Western blot analysis ( Figure 3C ). The specificity of the IL-21 effects was demonstrated by blunted BCL-2/BAX changes when using IL-21R small hairpin RNA (Figure 3B-3D ).
We next investigate whether STAT3 phosphorylation induced by IL-21 signaling is required for the survival effects of IL-21 treatment in hypoxic ECs. And found that STAT3 inhibition blunted IL-21 induced cell viability, tube formation ( Figure IX in the online-only Data Supplement), and BCL-2/ BAX increase ( Figure 3D ). To determine whether the increase of BCL-2 level induced by IL-21 signaling is required for the protective effects in ECs under HSS, we reduced BCL-2 level using small interfering RNA ( Figure X Necrosis grade is from 0 through 4, as described in Methods. Values are expressed as number of mice affected in each category/total number of mice in the category (%). Distribution is to the right. Interleukin-21 receptor knockout mice showed a higher necrosis rate compared with the wild-type littermates after HLI, although not statistically different.
Figure 4. Loss of interleukin-21 receptor (IL-21R) signaling results in impaired perfusion recovery after hindlimb ischemia (HLI). A, Laser
Doppler imaging showed significantly impaired perfusion recovery in Il21r −/− mice in C57BL/6 background compared with sex-matched and age-matched wild-type (WT) littermates at day 14 and 21 after HLI (n=9-12 per group). B, WT C57BL/6 mice that received 6 intraperitoneal doses of IL-21R-Fc fusion protein (200 mg/mouse at days 0, 1, 3, 7, 9, and 11 after HLI) showed significantly lower perfusion recovery when compared with vehicle-treated mice (control) at days 14 and 21 after HLI (n=11-12 per group). C, At day 21 after HLI, ischemic gastrocnemius muscle from Il21r −/− mice showed significant lower capillary density than WT littermates (n=9 per group). Average capillaries per muscle fiber: 1.6±0.1 vs 1.1±0.1; P<0.001. Data=mean±SEM. KO indicates Il21r knockout.
These data show that IL-21-mediated STAT3 phosphorylation and BCL-2 increase contribute to cell survival and tube formation in hypoxic ECs. Immunofluorescence staining shows that STAT3 and Caspase 3 were expressed in the ECs in the ischemic muscle tissue from HLI mouse model ( Figure XI in the online-only Data Supplement).
Removal of IL-21 Ligand or Knockout of IL-21R Impairs Perfusion Recovery and Increases Tissue Loss, In Vivo, After HLI
We monitored perfusion recovery after HLI in Il21r −/− mice compared with age-matched and sex-matched wild-type (WT) littermates and found that Il21r −/− mice showed attenuated perfusion recovery starting at day 14 and continued through day 21 after HLI ( Figure 4A ). Consistent with poorer perfusion recovery, Il21r −/− mice tended to show higher, although not statistically different, rates of tissue loss (Table) . Ischemic muscle tissue from Il21r −/− mice, 21 days after HLI, showed a lower capillary density than WT littermates ( Figure 4C ).
To determine whether IL-21R in leukocytes plays a role in the perfusion recovery after HLI, we measured the levels of several cytokines produced by leukocyte in the ischemic muscle tissue. Compared with WT mice, Il21r −/− mice do not show significant difference in the levels of monocyte chemotactic protein-1 (protein level, 8.9±2.6 versus 8.6±1.1 pg/μg total protein), IL-6 (protein level, 1.2±0.4 versus 0.8±0.2, n=5 pg/μg total protein), and vascular endothelial growth factor-A (mRNA level by quantitative real-time polymerase chain reaction; P=0.53). These may suggest that IL-21R knockout does not affect leukocyte secretion of certain cytokines.
The above data demonstrated that the IL-21R plays a role in perfusion recovery after HLI. To determine whether IL-21 ligand is also required, neutralizing IL-21R-Fc fusion protein was injected into WT C57BL/6 mice. 27 Similar to the results seen with Il21r −/− mice, neutralization of IL-21 resulted in impaired perfusion recovery compared with vehicle-treated mice ( Figure 4B ).
We then sought to determine if the IL-21 pathways found in HUVEC under HSS are present in muscle tissue in vivo. Consistent with the in vitro results, knockout of IL-21R decreased STAT3 phosphorylation 1 day after HLI when compared with tissue from WT mice ( Figure 5A ). However, Il21r −/− mice did not show any statistical difference in the phosphorylation of the other 3 proteins. Furthermore, on day 7 after HLI, as assessed by Western blotting, Il21r −/− mice showed a lower BCL-2/BAX ratio in the ischemic muscle tissue than did WT littermates ( Figure 5B ).
Discussion
Our study describes a new role for the IL-21 receptor-ligand axis in modulating perfusion recovery after HLI via receptor activation in hypoxic ECs after HLI. IL-21 is known to play a key role in innate and adaptive immunity and signals via a heterodimeric receptor formed by IL-21R and γ c and is known to regulate at least 4 pathways. 19, 25 Three of these pathways (STAT3, ERK1/2, and AKT-1) are known to enhance cell Figure 5 . Il21r knockout (KO) mice had decreased signal transducer and activator of transcription 3 (STAT3) phosphorylation and B-cell lymphoma leukemia-2 (BCL-2)/BCL-2-associated X protein (BAX) ratio after hindlimb ischemia (HLI). A, Consistent with in vitro data shown in Figure 3 , Il21r −/− mice showed less STAT3 phosphorylation in ischemic gastrocnemius muscle, but did not show any difference of STAT1, AKT, or ERK1/2 phosphorylation 1 day after HLI when compared with ischemic gastrocnemius muscle from the wild-type (WT) mice. B, In gastrocnemius muscle at day 7 after HLI, Il21r KO had a decreased BCL-2/BAX ratio. n=4 to 5 per group, Data=mean±SEM. NS indicates non statistical significance; p-AKT, phospho-AKT; p-ERK1/2, phosphor-ERK1/2; and p-STAT, phospho-STAT. survival and angiogenesis. [28] [29] [30] However, STAT1 activation can induce EC apoptosis and inhibit proliferation. 31 We began this study with the knowledge that the Il21r was possibly implicated as influencing the extent of recovery after HLI based on prior quantitative trait locus analysis, but Castermans et al 32 described that IL-21 ligand-mediated receptor activation inhibited basic fibroblast growth factor (b-FGF)-induced proliferation of cultured mouse ECs and decreased microvessel density within the tumors from a EG7 tumor-bearing mouse model, with the angiostatic properties being mediated through increased phosphorylation of STAT1 and decreased phosphorylation of STAT3. In totality, our study demonstrates that the effect of IL-21 on angiogenesis is likely to be context-and condition-dependent, with angiostatic effects being dominant when normal oxygen tensions are present and cytokines are abundant versus angiogenesis occurring when ECs are hypoxic and the receptor is upregulated and activated ( Figure 6 ). Previous studies have shown that IL-21 receptor activation has proapoptotic effects on B cells when B-cell receptor signaling is absent; however, in the presence of B-cell receptor signaling, IL-21 induces cell proliferation and differentiation. 33 Thus, there is precedent for differential effects by IL-21, depending on the context. STAT3 is a transcription factor that is activated by several cytokines and growth factors. On activation, STAT3 becomes phosphorylated on tyrosine residue (Y705) and forms homodimers that translocate to the cell nucleus, where they modulate the transcription of target genes. 28 STAT3 activation is found in ischemic tissue from a spectrum of ischemic diseases, including stroke and myocardial infarction, and functions as a protective factor to improve the recovery of these diseases. 34, 35 Interestingly, increased STAT3 phosphorylation was also found in the ischemic hindlimb muscle tissue when compared with muscle tissue from the healthy leg in our study ( Figure V in the online-only Data Supplement). Recent studies demonstrate that STAT3 activation improves tissue recovery from ischemia by increasing the expression of the antiapoptotic gene BCL-2 and by decreasing expression of proapoptotic gene BAX. 26, 36 A higher BCL-2/BAX ratio is related to better perfusion recovery from HLI. 37, 38 Consistent with these findings, our data suggest that loss of IL-21/IL-21R signaling results in impaired perfusion recovery after HLI correlated with reduction of BCL-2/ BAX ratio and inhibition of STAT3 activation ( Figure 6 ).
ECs are a major cell type involved in the perfusion recovery after HLI. Our data showed an elevated level of IL-21R in EC fractions from the ischemic hindlimb tissue when compared with the ECs from nonischemic hindlimb tissue, in the mouse strain with good perfusion recovery. Consistent with this, elevated IL-21R expression was also found in cultured ECs when cultured in HSS conditions, which mimic the in vivo ischemic condition. IL-21 treatment of ECs in the conditions with IL-21R elevation results in improved cell survival, tube formation, and reduced cell apoptosis. The protective effects on ECs in HSS conditions are related to IL-21-induced BCL-2/BAX increase via STAT3 activation. For myocytes and vascular smooth muscle cell in vitro, IL-21R was expressed in low to undetectable levels and did not show a change with hypoxia. These data suggest that elevated IL-21R levels in EC in ischemic muscle are adaptive, and IL-21R activation in ECs contributes to the perfusion recovery after HLI.
Vascular endothelial growth factor is a potent stimulant for the induction of EC migration, proliferation, repair, and survival via the AKT or ERK1/2 pathways. 39, 40 However, the use of vascular endothelial growth factor in human trials has been largely unsuccessful in the treatment of PAD. 6, 41 This suggests that modulation of the AKT and ERK1/2 pathways may not be beneficial in PAD treatment. We have shown that IL-21-induced angiogenesis requires STAT3 rather than AKT or ERK1/2, and exploring this pathway may be promising as an approach to identify new treatment options for PAD treatment provided the receptor is present and accessible to ligand.
Our data have other potential clinical implications. The role of IL-21 in autoimmune disease is broad, contributing to development of type 1 diabetes mellitus, systemic lupus erythematosus, and experimental allergic uveitis in animal models, 15, 18, 21, 33 suggesting both humoral and cellular immunologic contributions to autoimmune disease but none of these would exclude the treatment of the majority of patients with PAD. Interestingly, antagonists of IL-21 are also being evaluated for treating autoimmune diseases or after organ transplantation. The data from our study may prove to be important to understand potential safety issues if the patients treated in these trials have, or develop, PAD.
Currently, listings at http://www.clinicaltrials.gov show that recombinant IL-21 is currently being tested in at least 12 different clinical trials mostly being used in various malignancies. 17 Further studies of IL-21 treatment for HLI mouse model may provide the opportunity to allow for the rapid assessment of IL-21 to treat PAD.
Collectively, our data indicate that IL-21R upregulation in response to HLI may well be adaptive, and that IL-21 signaling in ECs may contribute to improved perfusion recovery after HLI by activating the STAT3 pathway and increasing the BCL-2/BAX ratio. Thus, IL-21R is a potential target for pharmacological modulation in PAD.
